Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Pfizer will report Q1 2026 earnings after market close, with analysts anticipating updates on its 2026 revenue and EPS targets alongside developments in oncology and obesity drugs. Consensus estimates ...
Pfizer Inc. PFE and partner Arvinas Inc. ARVN shares rose Monday after the companies secured a key regulatory win, with the U ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...
Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while signaling a pivot toward obesity drug programs as well as a larger slate of ...
(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...
Pfizer’s GLP-1 weight management treatment Xianweiying, is reportedly available for pre-order in China in the wake of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results